CNS Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note Payable

Note Payable	3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]
Note Payable	Note 3 – Note Payable On November 14, 2022, the Company entered into a short-term note payable for an aggregate of $449,874, bearing interest at 5.88% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over an 11-month period with the final payment due on October 31, 2023. As of March 31, 2023 and December 31, 2022, the Company’s note payable balance was $289,075 and $409,968, respectively.

Note Payable

3 Months Ended

Mar. 31, 2023

Note 3 – Note Payable

On November 14, 2022, the Company entered into a short-term note payable for an aggregate of $449,874, bearing interest at 5.88% per year to finance certain insurance policies. Principal and interest payments related to the note will be repaid over an 11-month period with the final payment due on October 31, 2023. As of March 31, 2023 and December 31, 2022, the Company’s note payable balance was $289,075 and $409,968, respectively.